Marapharm Ventures Inc (CNSX:MDM) (OTCMKTS:MRPHF) Re-Organizes As It Transitions Into Mainstream Marijuana Business

Marapharm Ventures Inc (CNSX:MDM) (OTCMKTS:MRPHF) has announced the onboarding of a new board member. In a press realease, the company has reported that Mr. Rahim S. Mohammed comes in to fill a position of an independent director following the departure of two others.

Mr. Rahim is reported to be currently serving as CEO of APPx Crypto Technologies Inc., and who has previously served as President, CEO and Internal Auditor for multiple private and public companies.

The new addition is also reported to have a rich experience in the world of investments, media relations and financing. With these qualities, Marapharm hopes that the director can help steer the strategy of the company to success.

Nevada Licensing Update

In another release, the company has reported that it has successfully applied for and received 19 city and state regulatory licenses and permits in Nevada. The company has reported that application process is rigorous and laborious at the same time. For that reason, the company has taken a long time to acquire the permits.

The release notes that the State of Nevada, Department of Taxation issued a notice seeking applications from qualified applicants to award recreational marijuana retail store licenses. Sadly, the release notes that the number of available licenses is limited and in addition, a qualified company can only be granted licenses for three stores in Las Vegas and surrounding jurisdictions.

However, the statement goes on to say that the company will still apply for more licenses. Per the CEO, Linda Sampson, the company will prepare and produce retail applications to the state “regardless of the scope of work and the narrow 14-day application period.”

Moving to permanent facilities

In other news, the company is reported to be moving to other permanent facilities where it will be able to clone several products for productions. This comes after the company was reported to have acquired cultivation assets, water and land rights from two licensed cannabis growers in Washington. In a statement, Marapharm Director of Operations Kurt Keating revealed that the company has moved several clones to the new facilities where they can be cultivated and harvested.


Marapharm Ventures Inc (OTCMKTS:MRPHF) Signs A LOI To Acquire Full Spectrum Medicinal Inc

Marapharm Ventures Inc (OTCMKTS:MRPHF) has signed a letter of intent to take over Full Spectrum Medicinal Inc. The company has set September 30, 2018, as the deadline to conduct due diligence on Full Spectrum and complete the acquisition.

Following the takeover, Marapharm Ventures will merge Full Spectrum application with Health Canada Application. It helps to become a licensed cannabis manufacturer of premium flower for commercial use. The company will be able to deliver organic and quality cannabis products in a cost-effective way and boost profits.

The business model of the company is to build standardized engineered bio-secure facilities. The state of the art facilities are scalable and saves energy and promote cost-effective cultivation. The company will be able to grow quality cannabis indoors at reduced costs. Marapharm Ventures will deliver the first assembly building at an approved site situated near the Salmon Arm, British Columbia.

The company is planning for penetration of the legal cannabis with edibles, oils, and flowers and build a long-term value in the rapidly growing market.

Canada Legalizes Marijuana

Justin Trudeau, Prime Minister, Canada has announced the legalization of marijuana on June 20, 2018. The legalization of marijuana comes into effect from October 17, 2018. It has put an end to the prohibition of cannabis in Canada.

Marapharm Ventures Inc Issues an Update on Market Activities to The Shareholders As Frankfurt’s Clearstream Closes Doors to The North American cannabis stocks

Marapharm Ventures Inc has issued an update on the recent market activities to the shareholders on the backdrop of Frankfurt’s Clearstream shutting the doors to North American Cannabis stocks.

Frankfurt, Germany based major central securities depository – Clearstream has set June 29, 2018, as the deadline as for final settlements free of fee. However, Clearstream will offer the services till September 28, 2018, and after that it will not settle the securities related to cannabis and narcotic products due to legal reasons.

The list of impacted securities include GW Pharmaceuticals PLC (NASDAQ:GWPH), Canopy Growth Corp (NYSE:CGC), Aurora Cannabis Inc (OTCMKTS:ACBFF), and Marapharm Ventures Inc.

Marapharm Ventures Inc has a number of Germany based shareholders. The company is making alternative arrangements in view of the sudden decision of Clearstream.

Marijuana Medical

Stocks In Focus: Vitality Biopharma Inc (OTCMKTS:VBIO) And Marapharm Ventures Inc. (OTCMKTS:MRPHF)

Vitality Biopharma Inc (OTCMKTS:VBIO) continues to be a unappreciated stock in the vibrant cannabis industry. It intends to aim NBS and IBD. Commencing in 2014, marijuana equities were in focus. Shareholders were analyzing the industry to list any firm that stated itself as an emerging entity in the buzzing cannabis market.

The shortcoming in that investment plan, though, was that many stockholders were too absent-minded while selecting a firm with an attractive title, rather than an entity that indeed boasted some substance. While investors were attracted by the illusion that profits would be fetched by putting money in these firms that purportedly envisioned to cultivate and sell recreational and medicinal based pot, they should have focused more on putting money in firms that are determined using the crop’s cannabinoid benefits, which are steadily exhibiting extraordinary advantage in curing certain medical ailments.

Having said that, if shareholders had only focused on seeking rewarding and realistic prospect via cannabis medications, Vitality Biopharma would have been regarded. It is one of 3 cannabinoid related entities that they witness as truly being able to produce any significant revenue in the forthcoming few years.

The so designated “green rush” that was in full swing in 2014 led investors to numerous penny shares, many of whom misguided stockholders with pipe dreams of attaining a position in the budding multi-billion-dollar pot business that has progressed through the legalization of pot laws in some of the states in the U.S. and abroad.

Another firm in the cannabis industry, Marapharm Ventures Inc. (OTCMKTS:MRPHF) has finalized a contract to acquire an industrial facility situated in southern California and 3 medicinal marijuana permits for retail, manufacturing and cultivate application.

In the last trading session, the stock price of MRPHF declined over 4% to close the day at $1.07. The decline came at a share volume of 67,330 compared to average share volume of 91,846.

Marijuana Medical

General Cannabis Corp (OTCMKTS:CANN) Positioning For Expansion Opportunities

With the demand for different facets of the cannabis market rushing behind momentum after election cycle, legal marijuana and cannabis based companies including General Cannabis Corp (OTCMKTS:CANN) are gaining by rapid expansion and launch of innovative products/services. Other firms active in the respective sector include Marapharm Ventures Inc. (OTCMKTS:MRPHF), AURORA CANNABIS IN COM NPV(OTCMKTS:ACBFF) and others.

Marapharm has entered into a contract to purchase an industrial facility sited in southern California and three medicinal marijuana licenses for retail, manufacturing and grow application. The land area is 40,510 square feet and the current building acreage is 6,875 square feet, with a clearance for 19-foot-ceiling, for an acquisition price of $3.2 million, depending on $450 per square foot for the edifice and $65 per square foot for the asset.

The yard part is paved and appropriate for greenhouse cultivation. Marapharm said that the purchase is dependent on the closure of satisfactory due diligence, comprising background checks, and necessary documentation for the release of the three licenses to company within 120 days, with the completion to take place after 120 days from the elimination of contingencies.

Linda Sampson, the CEO of Marapharm, reported that they are really excited to get such a prize asset as well as 3 licenses, and to be in this growing market in California. The ‘Yes’ vote in the state is significant for numerous reasons. They have 300,000 square feet of medicinal marijuana licenses, facilities and assets in WA and NV and, nearly two and a half years earlier, the company applied in Canada for a MMPR license, having since approved the necessary security nods. The application is in the in-depth screening procedure. In September, Health Canada approached Marapharm with a provision to modify its application to permit for the new guidelines, known as ACMPR.

In other developments, Terra Tech reported its third quarter 2016 results for the period closing September 30, 2016. The CEO Derek Peterson commented that they are encouraged to see their plan to expand retail presence is driving top line growth.


Is It Time To Stay Invested In General Cannabis Corp (OTCMKTS:CANN)?

General Cannabis Corp (OTCMKTS:CANN) showed exceptional performance in a sector-wide growth, however, it is notable to assess here is that the irrespective of a capital surge, the balance sheet of firm remains weak. It implies that its valuation of $125 million is not well-supported by fundamentals.

The buzz

General Cannabis equity witnessed remarkable up move during the election period this year. The firm, formerly known as ‘Advanced Cannabis Solutions’ and sited in Colorado, offers various services to the expanding industry, comprising security, advisory, apparel, supplies, real estate and branding. The equity did record strong up move, but it has plunged from the high of $5.19. It should be noted that it has surged more than 570% from level of $0.77 seen on August 31, 2016.

For stockholders who made money from their trades, analysts suggest that trades should be closed regardless of the recent drop of 28% from the high point. They are predicting the equity to go even lower in the imminent months. This cautious approach on the stock can be linked to the notable capital raised by firm.The capital generation noted in recent period, which was confirmed in an 8-K filing, can be the reason for the stock price drop.

General Cannabis raised $3 million via the release of warrants and promissory notes, with sum of $550,000 used to close prevailing debt and the amount indicating new funding. It has interest of 12% and is set to mature in 2019. The firm released 4.5 million warrants and 4.5 million warrants priced at $0.75 and $0.30, in that order. It presently has 15.6 million shares due, hence the 9 million warrants will boost the float rather considerably.

Also, with higher trading volumes, the 9 million warrants imply more than 10 times the count of traded shares daily on average in the preceding month.

Marapharm Ventures Inc. (OTCMKTS:MRPHF) gave timelines for Las Vegas project that was confirmed in PRs issued on November 14 and November 23, with updates followed on December 4 and December 6, 2016. The CEO, Linda Sampson, expressed that they are overwhelmed with the developments in marijuana industry. Almost 50 million adult visitors come to Nevada every year, which shows considerable growth prospects.


GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Says NDA Filing And Release Preparation On Track

Justin Gover, the CEO of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), said that in FY2016, the company has closed three promising Phase III studies for Epidiolex in subjects with two different rare cure resistant types of childhood-onset epilepsy and they are making strong advancement towards an NDA filing.

The sights are now concentrated on Epidiolex agreement and accelerating their preparations for a successful launch. Their objective is to offer the kids and their families struggling from these forms of childhood-onset epilepsy with a new prescription alternative as quickly as possible.

The updates

GW Pharmaceuticals reported that its revenue for the year closed September 30, 2016 came at £10.3 million compared to £28.5 million in the same period a year earlier. Loss for the year closed September 30, 2016 amounted to £63.7 million against £44.6 million for the year closed September 30, 2015. Cash/cash equivalents came at £374.4 million versus £234.9 million in the comparable period.

The company updated on the performance of Epidiolex® orphan epilepsy plan in Dravet syndrome, LGS, Tuberous Sclerosis Complex and infantile spasms Phase III studies. Positive results were reported in a pivotal Phase III Dravet syndrome trial and also from two pivotal Phase III LGS trials.

Coming to marijuana industry, Marapharm Ventures Inc. (OTCMKTS:MRPHF) provided timelines updates for its sought-after Las Vegas, Nevada project. The company has updated on this planned assignment first on November 14. Later it released additional PRs on November 23, and also on December 4 and 6, to provide more details.

Linda Sampson, the CEO of Marapharm, reported that they are thrilled as Nevada gets nearly 50 million adult tourists annually. Marijuana is legalized for both recreational and medicinal use in the regions, which makes them believe the potential is huge and they are all set to embrace the upcoming change. They have paid for the land, equipment, buildings, and other items. The company is in strong financial position with almost $4 million in cash as working capital for this project.

Pin It on Pinterest